Clinical Trials Logo

Depersonalization Disorder clinical trials

View clinical trials related to Depersonalization Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT02476435 Completed - Clinical trials for Depersonalization Disorder

Depersonalization Disorder: Therapeutic Effect of Neuronavigated Repetitive Transcranial Stimulation

PERSONA
Start date: June 19, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the therapeutic efficacy of transcranial magnetic stimulation in patients with depersonalization disorder.

NCT ID: NCT02256085 Recruiting - Clinical trials for Depersonalization Disorder

Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)

Start date: October 2013
Phase: Phase 2
Study type: Interventional

This is a randomized controlled trial (RCT) on the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of Depersonalization Disorder (DPD). TMS applies a magnetic field to the brain for a brief period of time. TMS is a procedure that involves 30 minute-long daily sessions every weekday for a series of weeks. The investigators are testing whether TMS can treat Depersonalization Disorder (DPD).

NCT ID: NCT00529217 Completed - Clinical trials for Depersonalization Disorder

Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)

TMS
Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy of transcranial magnetic stimulation in the treatment of Depersonalization Disorder (DPD).

NCT ID: NCT00004446 Completed - Clinical trials for Depersonalization Disorder

Study of Fluoxetine in Patients With Depersonalization Disorder

Start date: April 1998
Phase: N/A
Study type: Interventional

The purpose of this study is to: 1) Determine the effects of fluoxetine in the treatment of depersonalization disorder, 2) Assess the durability of treatment response in these patients, 3) Assess the improvement in psychiatric disability in these patients, and 4) Assess the effects of comorbid Axis I disorders (depression, social phobia, panic/anxiety, obsessive-compulsive disorder) and Axis II personality disorders on treatment outcome in these patients.